share_log

Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.

Benzinga ·  Nov 25 08:08
Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment